- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03784755
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)
A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The standard or usual treatment for this disease is systemic therapy, which includes androgen deprivation therapy (ADT) with or without chemotherapy or hormone therapy. Additionally, for some patients with specific disease features, standard treatment may also include ablative treatment (radiation or surgery) of the prostate gland if this was not completed prior to enrolling into this study.
Ablative Therapy is a procedure used to destroy cancer cells and tissue. In this study Stereotactic Body Radiation Therapy (SBRT) or surgery will be used to destroy prostate cancer metastases. It is not clear if ablative therapy (SBRT or surgery) to all sites of disease used in combination with standard systemic therapy can offer better results than standard treatment alone.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wendy Parulekar
- Phone Number: 613-533-6430
- Email: wparulekar@ctg.queensu.ca
Study Locations
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8R 6V5
- Recruiting
- BCCA - Vancouver Island Cancer Centre
-
Contact:
- Abraham S. Alexander
- Phone Number: 77094 250 519-5575
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Recruiting
- CancerCare Manitoba
-
Contact:
- Bashir Bashir
- Phone Number: 204 578-2208
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Recruiting
- QEII Health Sciences Centre
-
Contact:
- Nikhilesh Patil
- Phone Number: 902 473-6185
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Recruiting
- Royal Victoria Regional Health Centre
-
Contact:
- Adam Gladwish
- Phone Number: 705 728-9090
-
Hamilton, Ontario, Canada, L8V 5C2
- Recruiting
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contact:
- Kimmen Quan
-
Mississauga, Ontario, Canada, L5M 2N1
- Recruiting
- Trillium Health Partners - Credit Valley Hospital
-
Contact:
- Andrew Chiang
- Phone Number: 5115 905 813-1100
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- Ottawa Hospital Research Institute
-
Contact:
- Scott Morgan
- Phone Number: 70206 613 737-7700
-
Sault Ste. Marie, Ontario, Canada, P6B 0A8
- Recruiting
- Algoma District Cancer Program
-
Contact:
- Mohammad Rassouli
- Phone Number: 4450 705 759-3434
-
Sudbury, Ontario, Canada, P3E 5J1
- Recruiting
- Health Sciences North
-
Contact:
- Ryan Carlson
- Phone Number: 2451 705 522-6237
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- University Health Network
-
Contact:
- Peter Chung
- Phone Number: 6522 416 946-4501
-
Toronto, Ontario, Canada, M4N 3M5
- Recruiting
- Odette Cancer Centre
-
Contact:
- Patrick C.F. Cheung
- Phone Number: 416 480-6165
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- The Jewish General Hospital
-
Contact:
- M. Tamim Niazi
- Phone Number: 514 340-8288
-
Montreal, Quebec, Canada, H2X 3E4
- Recruiting
- CHUM-CEntre Hospitalier de l'Universite de Montreal
-
Contact:
- Maroie Barkati
- Phone Number: 514 890-8254
-
Montreal, Quebec, Canada, H1T 2M4
- Recruiting
- CIUSSS de l'Est-de-I'lle-de-Montreal
-
Contact:
- Peter Vavassis
- Phone Number: 514 252-3425
-
Quebec City, Quebec, Canada, G1R 2J6
- Recruiting
- Hotel-Dieu de Quebec
-
Contact:
- Isabelle Thibault
- Phone Number: 418 691-5181
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Recruiting
- Allan Blair Cancer Centre
-
Contact:
- Dilip Panjwani
- Phone Number: 306 766-2296
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Recruiting
- Saskatoon Cancer Centre
-
Contact:
- Ali El-Gayed
- Phone Number: 306 655-2740
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologic diagnosis/confirmation of prostate adenocarcinoma and no evidence of small cell cancer.
- Stage IV at presentation or relapse after curative intent therapy, classification per AJCC 8th edition: M1 disease with ≤ 5 metastases
- ≤ 3 metastases in any non-bone organ system
- Zoladex must commence within 12 weeks prior to randomization or within 12 weeks after randomization.
- Radiology (CT/MRI chest/abdomen/pelvis) within 42 days of randomization
- Bone scan within 42 days of randomization
- All tumours (Primary prostate and metastases) must be amenable to local ablative therapy (radiation and/or surgery).
- Age ≥ 18
- ECOG performance 0-1
- Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and economics questionnaires in either English or French
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
- Patients must be medically suitable for study treatments as assessed by the appropriate specialties: medical, radiation, and surgical
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
- In accordance with CCTG policy, ablative therapy to metastases is to begin within 6 weeks after patient randomization
- Men of childbearing potential must have agreed to use a highly effective contraceptive method to prevent pregnancy while on study
- Patient must consent to provision of, and Investigator must confirm location of and commit to obtain a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative studies described in the protocol may be conducted. Where tissue exists but local centre regulations prohibit submission of blocks of tumour tissue, the approval of the CCTG must be sought prior to randomization of the first patient to allow cores (two 2 mm cores of tumour from the block) and slides (20 x 5 micron thick unstained slides) of representative tumour tissue to be substituted
- Patient must consent to provision of samples of whole blood (for cfDNA) in order that the specific correlative studies described in the protocol may be conducted.
Exclusion Criteria:
- Prior treatment with ADT in the neoadjuvant or adjuvant setting, unless treatment was discontinued ≥ 12 months prior to randomization AND total duration of treatment was ≤ 36 months (including expiry of last depot injection).
- Previously diagnosed recurrent/metastatic disease which has been already treated with any systemic therapy or radiotherapy
- Castration resistant prostate cancer, defined as rising PSA (per PCWG3) or radiographic progression in the setting of castrate levels of serum testosterone (< 1.7 nmol/L).
- Patients who present with de novo stage IV disease with pelvic lymphadenopathy as their only site of metastases (N1 M0), where the primary prostate has never been treated with curative intent prostate surgery or radiotherapy in the past.
- Inability to treat all sites of disease with local ablative therapy
- Patients with parenchymal brain metastases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1 (standard of care)
Standard systemic therapy + Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden |
Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
|
Experimental: Arm 2 (standard systemic therapy + ablative therapy))
Local Ablative therapy to all sites of disease (including untreated prostate primary) + Standard systemic therapy |
Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Failure-free Survival
Time Frame: 6 years
|
defined as the time from randomization to the time of the first occurrence.
|
6 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiographic Progression-free Survival
Time Frame: 6 years
|
the comparison of these outcomes between the two treatment arms will be tested by the log-rank test
|
6 years
|
Incidence of new metastases as first event
Time Frame: 6 years
|
the comparison of these outcomes between the two treatment arms will be tested by the log-rank test
|
6 years
|
Overall Survival
Time Frame: 6 years
|
the comparison of these outcomes between the two treatment arms will be tested by the log-rank test
|
6 years
|
Ablative treatment related adverse events (>/= grade 3) using CTCAE v5.0
Time Frame: 6 years
|
6 years
|
|
Quality of Life measured by EORTC QLQ-C30
Time Frame: 6 years
|
It consists of both multi-item scales and single item measures, including five functioning domains, a global quality of life domain, three symptom domains and six single items.
For each domain or single item measure a linear transformation will be applied to standardize the raw score to range between 0 and 100
|
6 years
|
Quality of Life measured by Bone Metastases module (BM22)
Time Frame: 6 years
|
The BM22 has 22 questions consisting of the 4 subscales (painful sites (PS) and pain characteristics (PC) on the symptom scale and functional interference (FI) and psychosocial aspects (PA) on the functional scale).
Modules, relevant subscales will also be linear transformed to standardize the raw score to range between 0 and 100 in accordance with the EORTC scoring manuals.
|
6 years
|
Quality of Life measured by prostate (PR25) questionnaire module
Time Frame: 6 years
|
has 25 questions in four domains (urinary, bowel, sexual, and hormonal).
Modules, relevant subscales will also be linear transformed to standardize the raw score to range between 0 and 100 in accordance with the EORTC scoring manuals.
|
6 years
|
Economic analysis measured by EQ-5D-5L
Time Frame: 6 years
|
The robustness of the model results will be assessed using one-way and multi-way sensitivity analyses.
Major drivers of medical care costs, namely hospitalization, chemotherapy and survival, will be varied ± 20%, to examine the impact on the base-case incremental cost effectiveness ratios (ICERs).
Bootstrapping and the development of a cost-effectiveness acceptability curve will also be conducted.
|
6 years
|
Economic analysis by determining an incremental cost-effectiveness ratio reported as a difference in cost per FFS-year between the 2 arms
Time Frame: 6 years
|
6 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Patrick CF Cheung, Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto, ON Canada
- Study Chair: M. Tamim Niazi, The Jewish General Hospital, Montreal, QC Canada
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Metastatic
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Dana-Farber Cancer InstituteEpizyme, Inc.; PfizerRecruitingMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
Clinical Trials on Standard of care
-
brett rasmussenCompleted
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Ruijin HospitalRecruitingCOVID-19 PneumoniaChina
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
Ziv HospitalNot yet recruiting
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted